The FDA on January 17, 2012 approved VORAXAZE® for the treatment of toxic plasma methotrexate concentrations (> 1 μmol/L) in patients with delayed methotrexate clearance due to impaired renal function. VORAXAZE® is a product of BTG International Inc.
Bottom Ad
Advertisement
Subscribe
